Abstract
Anti-cancer drug development is a major area of research. Monitoring of response to newer anti-cancer drugs has undergone an evolution from structural imaging modalities to targeting functional metabolic activity at cellular level to better define responsive and non-responsive cancerous tissue. This review article highlights the contribution of Positron Emission Tomography (PET) in this field. PET holds a promising role in the future by providing us information pertaining to the drugs effectiveness early in the course of therapy, so that side effects and expenses can be reduced substantially. PET has been used to measure changes in drug induced metabolism, cellular proliferation and tissue perfusion. Also changes induced by immuno-modulating drugs such as apoptosis, telomere activity, growth factor levels and many more can be studied using specific radiolabelled PET tracers whereas conventional imaging modalities which detect changes in tumor size and residual tissue histopathology may not prove useful in such scenario. In future, most PET scanners will be replaced by Hybrid PET-CT scanners, which provide functional and structural information in the same setting. In addition, PET-CT improves characterization of equivocal lesions and decreases interobserver variability. The most important recent patents concerning role of PET in drug development have been presented.
Keywords: PET, PET-CT, drug development, therapy response
Recent Patents on Anti-Cancer Drug Discovery
Title: PET in Anti-Cancer Drug Development and Therapy
Volume: 2 Issue: 3
Author(s): Rakesh Kumar and Neena Lal
Affiliation:
Keywords: PET, PET-CT, drug development, therapy response
Abstract: Anti-cancer drug development is a major area of research. Monitoring of response to newer anti-cancer drugs has undergone an evolution from structural imaging modalities to targeting functional metabolic activity at cellular level to better define responsive and non-responsive cancerous tissue. This review article highlights the contribution of Positron Emission Tomography (PET) in this field. PET holds a promising role in the future by providing us information pertaining to the drugs effectiveness early in the course of therapy, so that side effects and expenses can be reduced substantially. PET has been used to measure changes in drug induced metabolism, cellular proliferation and tissue perfusion. Also changes induced by immuno-modulating drugs such as apoptosis, telomere activity, growth factor levels and many more can be studied using specific radiolabelled PET tracers whereas conventional imaging modalities which detect changes in tumor size and residual tissue histopathology may not prove useful in such scenario. In future, most PET scanners will be replaced by Hybrid PET-CT scanners, which provide functional and structural information in the same setting. In addition, PET-CT improves characterization of equivocal lesions and decreases interobserver variability. The most important recent patents concerning role of PET in drug development have been presented.
Export Options
About this article
Cite this article as:
Kumar Rakesh and Lal Neena, PET in Anti-Cancer Drug Development and Therapy, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (3) . https://dx.doi.org/10.2174/157489207782497190
DOI https://dx.doi.org/10.2174/157489207782497190 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer
Current Cancer Drug Targets A Potent Anti-Carcinoma and Anti-Acute Myeloblastic Leukemia Agent, AG490
Anti-Cancer Agents in Medicinal Chemistry Alteration of Isocitrate Dehydrogenase Following Acute Ischemic Injury as a Means to Improve Cellular Energetic Status in Neuroadaptation
CNS & Neurological Disorders - Drug Targets ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry Osteopontin is a Prognostic Factor in Patients with Advanced Gastric Cancer
Combinatorial Chemistry & High Throughput Screening Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design Ultrasound-Targeted Delivery Technology: A Novel Strategy for Tumor- Targeted Therapy
Current Drug Targets <i>In vivo</i> Anticancer Potential of Hydroxamic Acid Derivatives
Current Topics in Medicinal Chemistry Liquid Crystal Nanodispersions Enable the Cutaneous Delivery of Photosensitizer for Topical PDT: Fluorescence Microscopy Study of Skin Penetration
Current Nanoscience Inorganic Nanoparticles for Enhanced Photodynamic Cancer Therapy
Current Drug Discovery Technologies Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews Inflammatory Cytokines Pathways as Potential Therapeutic Targets for Gastric Cancer
Current Cancer Therapy Reviews Emerging Therapeutic Targets and Agents for Glioblastoma Migrating Cells
Anti-Cancer Agents in Medicinal Chemistry Engineered Liposomes for Drug Delivery and Biomedical Imaging
Recent Patents on Nanomedicine Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Nanoparticle Coated Viral Vectors for Gene Therapy
Current Biotechnology Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism